Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{189790,
        author = {Hitanshu Kumar and Ishu Garg},
        title = {UNDERSTANDING THE USE OF TRANSDERMAL PATCHES IN PSORIASIS: A LITERATURE REVIEW FROM 2020-2025},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {4638-4646},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=189790},
        abstract = {Psoriasis is a chronic, immune-mediated inflammatory skin disorder that requires long-term management and poses significant challenges due to impaired skin barrier function and systemic side effects associated with conventional therapies. Transdermal drug delivery systems, particularly transdermal patches, have emerged as a promising alternative to oral and injectable treatments by enabling localized, controlled, and minimally invasive drug administration. This review highlights recent advancements in transdermal patch technologies for psoriasis therapy, with a specific focus on microneedle-assisted systems, nanocarrier-integrated patches, and multifunctional wearable platforms developed between 2020 and 2025. Advanced transdermal patches incorporating nanocarriers such as liposomes, ethosomes, cubosomes, mesoporous silica nanoparticles, and nanosuspensions have demonstrated enhanced skin penetration, sustained drug release, and improved therapeutic efficacy. Microneedle-based patches further overcome the thickened psoriatic stratum corneum by creating transient microchannels, enabling efficient delivery of corticosteroids, immunosuppressants, small-molecule inhibitors, peptides, proteins, and even gene-editing agents. Recent studies also emphasize dual-drug and stimuli-responsive systems that combine rapid anti-inflammatory action with long-term immunomodulation, resulting in superior disease control and reduced systemic toxicity. Preclinical and early clinical investigations consistently report significant reductions in psoriatic severity indices, inflammatory cytokines, and epidermal hyperplasia, alongside improved patient compliance and safety profiles. Despite remaining challenges related to large-scale manufacturing, regulatory approval, and long-term safety assessment, transdermal patch-based drug delivery systems represent a transformative approach for personalized and targeted psoriasis therapy.},
        keywords = {Psoriasis; Transdermal patches; Microneedles; Nanocarriers; Controlled drug delivery},
        month = {January},
        }